Scientists probe shared link between severe COVID and blood cancers
NCT ID NCT04953312
Summary
This study aimed to understand how severe COVID-19 disrupts the body's ability to make new blood cells, a process called emergency hematopoiesis. Researchers planned to compare blood cell samples from three groups: patients with severe COVID-19, patients with certain chronic blood cancers, and healthy people. The goal was to learn how a specific protein, calprotectin, might drive this disruption, to identify potential future treatment targets. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy Institut
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.